Skip to content

Predictive value of sST2 for the incidence of contrast nephropathy in patients with acute non ST elevation myocardial infarction or unstable angina pectoris after PCI

Predictive value of sST2 for the incidence of contrast nephropathy in patients with acute non ST elevation myocardial infarction or unstable angina pectoris after PCI

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800019518
Enrollment
Unknown
Registered
2018-11-16
Start date
2018-12-01
Completion date
Unknown
Last updated
2018-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute non ST elevation myocardial infarction and unstable angina pectoris, contrast nephropathy

Interventions

Low sST2 group:Clinical diagnosis of non-STEMI or unstable angina pectoris with percutaneous coronary intervention.
HypersST2 group:Clinical diagnosis of non-STEMI or unstable angina pectoris with percutaneous coronary intervention.

Sponsors

Zhongda Hospital of Southeast University Medical School
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Patients who will be admitted to hospital from December 1, 2018 to December 1, 2019 are clinically diagnosed as acute non ST elevation myocardial infarction or unstable angina pectoris and PCI. Inclusion criteria: (1) aged 18 to 85 years old; (2) definitely diagnosed as acute non ST elevation myocardial infarction or unstable angina pectoris combined with emergency PCI.

Exclusion criteria

Exclusion criteria: (1) iodine or iodine contrast agent allergy; (2) end-stage renal disease and renal transplantation requiring peritoneal and hemodialysis; (3) severe cardiac insufficiency and valvular disease, and hemodynamic instability; (4) clear bacterial and fungal infections, acute and chronic inflammatory diseases, autoimmune diseases, tumors, etc.; (5) antibiotic treatment before admission; (6) contrast test should be applied within 2 weeks before admission; (7) use of nephrotoxic drugs during hospitalization.

Design outcomes

Primary

MeasureTime frame
sST2;

Secondary

MeasureTime frame
Cysc;creatinine;

Countries

China

Contacts

Public ContactChengchun Tang

Department of Cardiology, Zhongda Hospital of Southeast University Medical School

tangchengchun@hotmail.com+86 13914705570

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026